Matrix metalloproteinase polymorphisms and HIV anti-retroviral drugs: new implications of pharmacogenomics in therapeutic approaches.
Mannello
F
F
Department of Biomolecular Sciences, Section of Clinical Biochemistry, Faculty of Sciences and Technologies, University Carlo Bo, Via O, Ubaldini 7, Urbino (PU) 61029, Italy. ferdinando.mannello@uniurb.it
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000235:genetics; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000235:genetics*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
D019380:Anti-HIV Agents; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases; D020780:Matrix Metalloproteinase 9